The Readout Loud

350 Episodes

1. 308: An ASCO preview & another Duchenne trial failure

   Published: 5/30/2024
2. 307: More tumult at BIO & coercive care for sickle cell patients

   Published: 5/23/2024
3. 306: Live! From the STAT Breakthrough Summit West

   Published: 5/16/2024
4. 305: Everything you need to know about H5N1 bird flu

   Published: 5/9/2024
5. 304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

   Published: 5/2/2024
6. 303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc

   Published: 4/18/2024
7. 302: Vertex's big deal, biotech's red numbers, & an industry history lesson

   Published: 4/11/2024
8. 301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

   Published: 4/4/2024
9. 300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

   Published: 3/28/2024
10. 299: Live! From the STAT Breakthrough Summit East

    Published: 3/21/2024
11. 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

    Published: 3/14/2024
12. 297: VC turmoil, GLP-1 competition, & the war on recovery

    Published: 3/7/2024
13. 296: Legal insider trading, booming biotech stocks, & the next GLP-1

    Published: 2/29/2024
14. 295: Humira’s legacy, CEO symbolism, and genomic surgery

    Published: 2/22/2024
15. 294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

    Published: 2/15/2024
16. 293: AI in medicine, detangling hype, and Icelandic DNA

    Published: 2/8/2024
17. 292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

    Published: 2/1/2024
18. 291: The plight of the VC, Gilead's latest setback, & more M&A

    Published: 1/25/2024
19. 290: Biotech layoffs, slumping stocks, and a 2024 preview

    Published: 1/18/2024
20. 289: Live! From #JPM24

    Published: 1/11/2024